Polymeric drug delivery systems (PDDS) play a crucial role in controlled drug release, providing improved therapeutic outcomes. However, formulating PDDS and predicting their release profiles remain challenging due to their complex structures and the numerous variables that influence their behavior. Traditional mathematical and empirical prediction methods are limited in capturing these complexities. Recent studies have unveiled the potential of Machine Learning (ML) in revolutionizing drug delivery, particularly in formulating complex PDDS. This article provides an overview of the significant and fundamental principles of various ML strategies in estimating PDDS drug release behavior. Our focus extends to the accomplishments and pivotal discoveries in current research, spanning seven distinct sustained-release drug delivery systems: matrix tablets, microspheres, implants, hydrogels, films, 3D-printed dosage forms, and other innovations. Furthermore, it addresses the challenges associated with ML-based drug release prediction and presents current solutions while delving into future perspectives. Our investigation underscores the significance of Artificial Neural Networks in ML-based PDDS release profile prediction, surpassing both traditional and alternative ML-based methods. These extensive datasets can be drawn from literature-based resources or enhanced through specific algorithms. Moreover, ensemble-based models have proven advantageous in scenarios involving intricate relationships, such as a high number of output parameters. ML-based drug release prediction notably exhibits substantial promise in 3D-printed dosage forms, presenting a frontier for personalized medicine and precise drug delivery.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.compbiomed.2025.109756DOI Listing

Publication Analysis

Top Keywords

drug release
20
drug delivery
20
delivery systems
12
drug
10
machine learning
8
polymeric drug
8
3d-printed dosage
8
dosage forms
8
ml-based drug
8
release prediction
8

Similar Publications

Purpose: To evaluate and contrast the effectiveness and safety of two conbercept treatment protocols-a three-dose treat-and-extend (3+T&E) regimen and a three-dose pro re nata (3+PRN) regimen-in Chinese patients diagnosed with neovascular age-related macular degeneration (nAMD).

Methods: Eligible patients, who had not undergone anti-VEGF intraocular injections within 3 months prior to enrollment, were randomly assigned to either the 3+T&E or 3+PRN regimen. The 3+T&E group received at least three monthly injections, with subsequent visit intervals extended based on disease activity assessment.

View Article and Find Full Text PDF

Multiple myeloma (MM) is a malignant disease of plasma cells that accounts for approximately 10% of all hematological malignancies and is characterized by a clonal proliferation of malignant plasma cells in the bone marrow. Numerous therapeutic strategies, including proteasome inhibitors, immunomodulators, monoclonal antibodies against CD38 and autologous stem cell transplantation, have prolonged the median survival of MM patients. Nevertheless, almost all MM patients suffer disease relapses due to drug resistance and eventually die from MM or MM-related complications.

View Article and Find Full Text PDF

Characterizing the Use of Prolonged-Release Once-Daily Tacrolimus (LCPT) across Canada.

Can J Hosp Pharm

March 2025

, BSP, PharmD, PhD, is with the College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan.

Background: Tacrolimus is the most common calcineurin inhibitor given to kidney and liver transplant recipients. Prolonged-release once-daily tacrolimus (LCPT) is the newest formulation of this drug, but prescribing practices for tacrolimus across Canada are unknown.

Objectives: To investigate the use of tacrolimus across Canada, by determining coverage for the drug, exploring prescribing practices and factors related to decision-making, and identifying management methods for patients with rapid metabolism of tacrolimus.

View Article and Find Full Text PDF

An overview of oral bioavailability enhancement through self- emulsifying drug delivery systems.

Expert Opin Drug Deliv

March 2025

Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innsbruck, Austria.

Introduction: The pharmaceutical technologists face a lot of challenges and limitations when designing novel drug delivery systems such as low oral bioavailability of many drugs, primarily due to poor solubility, slow dissolution rates, limited permeability through gastrointestinal mucosa, and rapid degradation within the body. Areas covered: The biopharmaceutical classification (BCS) classification represents a map in drug delivery research. Numerous active ingredients are characterized by low bioavailability due to poor water solubility, especially active ingredients of BCS class II and IV.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!